Indium-111-DOTA-girentuximab-IRDye800CW

N/A

Report date: 2025/10/20 14:43:47

Base Information

Drug NameIndium-111-DOTA-girentuximab-IRDye800CW
Drug Alias Name111In-girentuximab-F2
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnostics +[7] 
Mechanisms of ActionCarbonic anhydrase IX bindersPositron-emission tomography enhancers
TargetsCarbonic anhydrase IX
Therapy Area/IndicationsDiagnostic agentsCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesRadboud University Nijmegen
China Registration ClassN/A

Develop Information

Active CompaniesRadboud University Nijmegen
Inactive CompaniesN/A
Active IndicationsDiagnostic agentsCarcinoma, Renal Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A